Haejin In

Haejin In


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
VTVasileios Tsagkalidis
Vasileios Tsagkalidis
MBMaryjka Blaszczyk
Maryjka Blaszczyk
HIHaejin In
Haejin In
Gastric cancer is among the top five causes of cancer-related death worldwide. Preoperative chemotherapy has been established as an option in patients with locally advanced gastric cancer. However, chemotherapy yields variable results, owing to the cellular and molecular heterogeneity of this disease. Identifying patients who did or did not respond to preoperative therapy can allow clinicians to alter treatment modalities and provide important information related to prognostication. A pathologic response to preoperative therapies, called the Tumor Response Grade (TRG), has been evaluated to quantify treatment response. Multiple systems for TRG have been established. However, the literature has demonstrated inconsistent results for TRG systems and prognosis, possibly due to variability in interpretation of tumor response between systems and interobserver variability. Radiographic responses to preoperative therapies using RECIST 1.1 criteria and endoscopically assessed tumor response have demonstrated association with survival; however, their use in gastric cancer remains challenging given the inability to accurately and consistently identify and measure the tumor, especially in the setting of neoadjuvant therapy, where treatment-related changes can obscure the gastric wall layers. While the response to preoperative therapies with positron emission tomography (PET) has shown promising results in esophageal and esophagogastric junction (EGJ) malignancies, its role in gastric cancer is still under investigation. This review is focused on summarizing the available literature related to evaluating TRG in gastric cancer, as well as providing a brief overview of the use of radiographic and endoscopic methods to assess response to preoperative therapies. Lastly, we outline future directions regarding the use of a universal TRG system to guide care and assist with prognosis.

3 July 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
VTVasileios Tsagkalidis
Vasileios Tsagkalidis
MBMaryjka Blaszczyk
Maryjka Blaszczyk
HIHaejin In
Haejin In
Gastric cancer is among the top 5 causes of cancer-related death worldwide. Preoperative chemotherapy has been established as an option in patients with locally advanced gastric cancer. However, chemotherapy yields variable results, owing to the cellular and molecular heterogeneity of this disease. Identifying patients who did or did not respond to preoperative therapy can allow clinicians to alter treatment modalities and provide important information related to prognostication. Pathologic response to preoperative therapies, called Tumor Response Grade (TRG), has been evaluated to quantify treatment response. Multiple systems for TRG have been established. However, literature has demonstrated inconsistent results for TGR systems and prognosis, possibly due to variability in interpretation of tumor response between systems and interobserver variability. Radiographic response to preoperative therapies using RECIST 1.1 criteria and endoscopically-assessed tumor response have demonstrated association with survival; however their use in gastric cancer remains challenging given the inability to accurately and consistently identify and measure the tumor, especially in the setting of neoadjuvant therapy where treatment-related changes can obscure the gastric wall layers. This review is focused on summarizing the available literature related to evaluating TRG in gastric cancer, as well as providing a brief overview on the use of radiographic and endoscopic methods to assess response to preoperative therapies. Lastly, we outline future directions regarding the use of a universal TRG system to guide care and assist with prognosis.

14 July 2026 in Annals of Surgical Oncology
Verified
Journal Article
Open access
AAAlexandra Adams
Alexandra Adams
KCKatherine De La Torre Cisneros
Katherine De La Torre Cisneros
BRBrijesh Rana
Brijesh Rana
HTHayavadhan Thuppal
Hayavadhan Thuppal
MEMariam F Eskander
Mariam F Eskander
HIHaejin In
Haejin In
This study aimed to identify the incidence of clinical understaging in early gastric cancer (GC) and to identify variables associated with increased risk of a patient being understaged. Clinical stage I (T1/2 N0) GC patients undergoing oncologic resection without neoadjuvant therapy from 2013 to 2020 were identified in the National Cancer Database (NCDB). Patients found to have a higher stage of cancer on final pathologic review were considered understaged. Clinicopathologic predictors of understaging were identified using multivariable logistic regression. The relationship between identified variables and understaging was modeled using logistic regression with natural cubic splines to allow for a flexible, nonlinear analysis. Cox proportional hazards analysis and Kaplan-Meier curves were used to evaluate survival outcomes. The study identified 4370 clinical stage I GC patients, 36% of whom were initially understaged on clinical staging. Tumor size per millimeter increase (OR, 1.05; 95% confidence interval CI 1.04-1.05; p < 0.001), higher grade (moderate: OR, 2.76; 95% CI 1.99-3.84; poor/anaplastic status: OR, 5.99; 95% CI 1.99-3.84, p < 0.001), and non-academic treatment facilities (OR, 1.19; 95% CI 1.03-1.38; p = 0.017) were associated with increased risk of understaging. Spline analysis showed increased risk of understaging based on tumor size. This was compounded when tumor differentiation was considered, such that a tumor measuring 2.5 cm was associated with 16.9%, 31.8%, or 51.6% likelihood of clinical understaging if the tumor was well, moderately, or poorly differentiated, respectively. Understaging was associated with increased mortality (OR, 2.31; 95% CI 2.10-2.95; p < 0.001). More than one third of clinical stage I GC patients are understaged. Tumor grade and size should be considered at preoperative evaluation of early GC to improve identification of patients at risk for understaging.

1 November 2023 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
KCKevin D Cassel
Kevin D Cassel
HIHaejin In
Haejin In
SSSrawani Sarkar
Srawani Sarkar
BRBruce Rapkin
Bruce Rapkin
GUGoyal Umadat
Goyal Umadat
Objective: Gastric cancer (GC) disproportionately affects ethnic minorities in the US including Asians and Pacific Islanders. Research with minority groups who are at high risk are needed to provide more effective treatment. Successful recruitment of minorities to research must overcome obstacles of language, access, fear and mistrust. Respondent Driven Sampling (RDS) is a sampling strategy designed to recruit underrepresented minority populations using social networks. However, there are no reports of RDS being used for a case-control study. Methods: Our pilot study examined the feasibility of using RDS as a recruitment strategy to enroll a large number of participants to develop a GC screener. Our preliminary work showed that 750 cases and 5,250 controls would be needed to fully develop this tool. GC cases, who also served as the seeds, were asked to refer 2 more people to participate as controls in our study. Our pilot goal was to recruit 8 GC cases (as seeds) and 112 controls using three waves of referrals and recruitment. Results: Twenty-seven GC cases were contacted of which 10 refused, 4 expressed interested to participate in the survey but were unwilling to recruit controls. Thirteen cases were recruited but only 5 comple4he survey. Of these 5, 3 cases did not pass on referral coupons and only 2 of the participants gave coupons to 3 potential controls. Conclusion: Our study revealed the limitations of using RDS with cancer patients to support recruitment. GC patients’ constrained social networks, inadequate incentives or other factors may have contributed to the lack of success with using RDS in this setting.

17 July 2026 in Annals of Surgical Oncology
Verified
Journal Article
Open access
AAAlexandra Adams
Alexandra Adams
HIHaejin In
Haejin In